J u m p t o c o n t e n t
M a i n m e n u
M a i n m e n u
N a v i g a t i o n
● M a i n p a g e
● C o n t e n t s
● C u r r e n t e v e n t s
● R a n d o m a r t i c l e
● A b o u t W i k i p e d i a
● C o n t a c t u s
● D o n a t e
C o n t r i b u t e
● H e l p
● L e a r n t o e d i t
● C o m m u n i t y p o r t a l
● R e c e n t c h a n g e s
● U p l o a d f i l e
S e a r c h
Search
A p p e a r a n c e
● C r e a t e a c c o u n t
● L o g i n
P e r s o n a l t o o l s
● C r e a t e a c c o u n t
● L o g i n
P a g e s f o r l o g g e d o u t e d i t o r s l e a r n m o r e
● C o n t r i b u t i o n s
● T a l k
( T o p )
1
M e d i c a l u s e s
2
P h a r m a c o l o g y
3
M a n u f a c t u r i n g
4
C l i n i c a l t r i a l s
5
A u t h o r i z a t i o n s
6
S e e a l s o
7
R e f e r e n c e s
T o g g l e t h e t a b l e o f c o n t e n t s
F A K H R A V A C
7 l a n g u a g e s
● ا ل ع ر ب ي ة
● C a t a l à
● Č e š t i n a
● ف ا ر س ی
● 日 本 語
● У к р а ї н с ь к а
● T i ế n g V i ệ t
E d i t l i n k s
● A r t i c l e
● T a l k
E n g l i s h
● R e a d
● E d i t
● V i e w h i s t o r y
T o o l s
T o o l s
A c t i o n s
● R e a d
● E d i t
● V i e w h i s t o r y
G e n e r a l
● W h a t l i n k s h e r e
● R e l a t e d c h a n g e s
● U p l o a d f i l e
● S p e c i a l p a g e s
● P e r m a n e n t l i n k
● P a g e i n f o r m a t i o n
● C i t e t h i s p a g e
● G e t s h o r t e n e d U R L
● D o w n l o a d Q R c o d e
● W i k i d a t a i t e m
P r i n t / e x p o r t
● D o w n l o a d a s P D F
● P r i n t a b l e v e r s i o n
I n o t h e r p r o j e c t s
● W i k i m e d i a C o m m o n s
A p p e a r a n c e
F r o m W i k i p e d i a , t h e f r e e e n c y c l o p e d i a
FAKHRAVAC (Persian : واکسن فخرا ) is a COVID-19 vaccine developed in Iran by the Organization of Defensive Innovation and Research ,[1] a subsidiary of Iran's Ministry of Defense . It is the third Iranian COVID-19 vaccine reaching clinical trials .[1] [2] [3] It is currently in phase III .[4] [5] It received emergency use authorization in Iran on 9 September 2021.[4]
The vaccine is named after the Iranian nuclear scientist Mohsen Fakhrizadeh .[1] According to the Iranian authorities, he was working on a vaccine in response to the COVID-19 pandemic in Iran .[1] [6] Fakhrizadeh was assassinated in November 2020 in an attack Iran and US intelligence attributed to Israel.[1] [7]
Medical uses [ edit ]
It requires two doses given by intramuscular injection 3 weeks apart.[5]
Pharmacology [ edit ]
FAKHRAVAC is an inactivated virus-based vaccine .[3]
Manufacturing [ edit ]
In August 2021, production capacity of the vaccine was reported to be 1 million dose per month and was planned to be "multiplied in a few months ".[4] In October 2021, the production was reported to be stopped amid Iran's growing vaccine imports.[8] In January 2022, the Director General of Health of the Ministry of Defense announced that the first shipment (around 462,000 doses) of the vaccine had been delivered to the Iranian Ministry of Health.[9]
Clinical trials [ edit ]
Authorizations [ edit ]
FAKHRAVAC received emergency use authorization in Iran on 9 September 2021.[4] In October 2021, Iran's Food and Drug Administration was considering giving full authorization to the vaccine for third/booster dose.[8]
See also [ edit ]
References [ edit ]
^ a b "Phase 2 trial of safety and immunogenicity of 10 micro gram inactivated SARS-CoV-2 vaccine (FAKHRAVAC), two doses two weeks apart in adults aged 18-70 years: a randomized, double-blind, placebo-controlled, clinical trial" . en.irct.ir . Iran Registry of Clinical Trials. Retrieved 15 June 2021 .
^ a b c d "Iran Authorizes Emergency Use of Third Homegrown Vaccine - Defense news" . Tasnim News Agency . Retrieved 9 September 2021 .
^ a b "IRCT | Comparison of the safety, efficacy and immunogenicity of Fakhravac and Sinopharm SARS-CoV-2 vaccines, in adults aged 18 and over; a phase III randomised, non-inferiority clinical trial" . en.irct.ir . Archived from the original on 7 September 2021. Retrieved 7 September 2021 .
^ "Research center run by Fakhrizadeh produced first COVID-19 test kits for Iranians: Defense minister" . Pars Today . 28 November 2020. Archived from the original on 5 December 2020. Retrieved 7 September 2021 .
^ The Assassination of Fakhrizadeh: Considerations and Consequences
^ a b Sinaee, Maryam (19 October 2021). "Iran Defense Ministry's Covid Vaccine Production To Be Discontinued" . Iran International. Retrieved 24 October 2021 .
^ "تحویل نخستین محموله واکسن فخرا به وزارت بهداشت" . YJC News . 19 January 2022.
t
e
Development
Classes
Administration
Vaccines
Inventors/ researchers
Controversy
Related
Clinical trials :
t
e
Institutions
Hospitals and medical clinics
Organizations
Global
By location
Health institutes
Pandemic institutes
Relief funds
People
Medical professionals
Researchers
Officials
Others
Deaths
Data (templates)
Global
Africa
Americas
Asia
Europe
Oceania
Others
Viruses
COVID-19
R e t r i e v e d f r o m " https://en.wikipedia.org/w/index.php?title=FAKHRAVAC&oldid=1215798672 "
C a t e g o r i e s :
● I r a n i a n C O V I D - 1 9 v a c c i n e s
● S c i e n c e a n d t e c h n o l o g y i n I r a n
● I n a c t i v a t e d v a c c i n e s
H i d d e n c a t e g o r i e s :
● A r t i c l e s w i t h s h o r t d e s c r i p t i o n
● S h o r t d e s c r i p t i o n i s d i f f e r e n t f r o m W i k i d a t a
● U s e d m y d a t e s f r o m J u n e 2 0 2 1
● D r u g s w i t h n o n - s t a n d a r d l e g a l s t a t u s
● C h e m i c a l a r t i c l e s w i t h o u t C A S r e g i s t r y n u m b e r
● A r t i c l e s w i t h o u t E B I s o u r c e
● C h e m i c a l p a g e s w i t h o u t C h e m S p i d e r I D
● C h e m i c a l p a g e s w i t h o u t D r u g B a n k i d e n t i f i e r
● A r t i c l e s w i t h o u t K E G G s o u r c e
● A r t i c l e s w i t h o u t I n C h I s o u r c e
● A r t i c l e s w i t h o u t U N I I s o u r c e
● D r u g s m i s s i n g a n A T C c o d e
● A r t i c l e s c o n t a i n i n g u n v e r i f i e d c h e m i c a l i n f o b o x e s
● D r u g s t h a t a r e a v a c c i n e
● A r t i c l e s c o n t a i n i n g P e r s i a n - l a n g u a g e t e x t
● W e b a r c h i v e t e m p l a t e w a y b a c k l i n k s
● T h i s p a g e w a s l a s t e d i t e d o n 2 7 M a r c h 2 0 2 4 , a t 0 5 : 2 9 ( U T C ) .
● T e x t i s a v a i l a b l e u n d e r t h e C r e a t i v e C o m m o n s A t t r i b u t i o n - S h a r e A l i k e L i c e n s e 4 . 0 ;
a d d i t i o n a l t e r m s m a y a p p l y . B y u s i n g t h i s s i t e , y o u a g r e e t o t h e T e r m s o f U s e a n d P r i v a c y P o l i c y . W i k i p e d i a ® i s a r e g i s t e r e d t r a d e m a r k o f t h e W i k i m e d i a F o u n d a t i o n , I n c . , a n o n - p r o f i t o r g a n i z a t i o n .
● P r i v a c y p o l i c y
● A b o u t W i k i p e d i a
● D i s c l a i m e r s
● C o n t a c t W i k i p e d i a
● C o d e o f C o n d u c t
● D e v e l o p e r s
● S t a t i s t i c s
● C o o k i e s t a t e m e n t
● M o b i l e v i e w